US · AGEN
Agenus Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Lexington, MA 02421-7305
- Website
- agenusbio.com
Price · as of 2024-12-31
$3.84
Market cap 113.25M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $8.36 | +117.71% |
| Intrinsic Value(DCF) | $0.94 | -75.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $256.07 | +6,568.41% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $114.23 | $77.68 | $0.00 | $0.00 | $0.00 |
| 2011 | $86.36 | $55.57 | $0.00 | $0.00 | $10.63 |
| 2012 | $86.56 | $135.62 | $3.91 | $0.00 | $0.00 |
| 2013 | $86.16 | $1,999.48 | $0.00 | $0.00 | $153.29 |
| 2014 | $106.38 | $99.49 | $1.67 | $0.00 | $0.00 |
| 2015 | $78.51 | $31.40 | $10,375.84 | $0.00 | $0.00 |
| 2016 | $81.06 | $32.42 | $15.43 | $0.00 | $13.95 |
| 2017 | $112.86 | $45.14 | $362.79 | $0.00 | $0.00 |
| 2018 | $52.40 | $20.96 | $0.00 | $0.00 | $157.20 |
| 2019 | $47.89 | $103.39 | $522,189.14 | $0.00 | $0.00 |
| 2020 | $64.97 | $56.31 | $0.00 | $0.00 | $656.06 |
| 2021 | $55.15 | $185.10 | $71,078.34 | $0.00 | $0.00 |
| 2022 | $29.44 | $1,641.44 | $0.00 | $0.00 | $871.18 |
| 2023 | $13.40 | $5.36 | $0.29 | $0.00 | $0.00 |
| 2024 | $2.35 | $8.36 | $0.00 | $0.00 | $256.07 |
AI valuation
Our deep-learning model estimates Agenus Inc.'s (AGEN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $8.36
- Current price
- $3.84
- AI upside
- +117.71%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.94
-75.52% upside
Graham-Dodd
—
— upside
Graham Formula
$256.07
+6,568.41% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AGEN | Agenus Inc. | $3.84 | 113.25M | +118% | -76% | — | +6,568% | -0.22 | -0.15 | 0.49 | -1.04 | — | -0.14 | -50.79% | -116.44% | -219.61% | 95.45% | 58.03% | -86.00% | -0.29 | -1.02 | 0.21 | 0.18 | -0.54 | -2298.00% | -3381.00% | -3214.00% | -314.88% | -0.72 | 76.54% | 0.00% | 0.00% | 0.00% | -0.87 | -0.66 | 1.01 | -15.68 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| FATE | Fate Therapeutics, Inc. | $1.48 | 170.72M | +1,664% | -45% | — | +3,067% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| HURA | TuHURA Biosciences, Inc. | $1.67 | 94.32M | — | — | — | — | -1.80 | 2.67 | — | -1.52 | — | 2.67 | 0.00% | — | — | -332.67% | 4773.62% | -178.25% | 0.01 | -4.26 | 3.68 | 2.42 | 0.71 | -8925.00% | — | 2291.00% | -37.91% | -2.76 | 3999.15% | 0.00% | 0.00% | 28.55% | -1.50 | -1.80 | — | -5.49 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| TTRX | Turn Therapeutics Inc. | $3.60 | 106M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 3858.47% | 179.80% | -87.06% | -0.68 | — | 1.55 | 1.23 | 0.43 | — | — | 273.00% | — | -1.92 | 146.15% | — | 0.00% | — | — | — | — | — |
| VTGN | VistaGen Therapeutics, In… | $0.59 | 19.2M | +3,740% | +110% | — | +12,444% | -1.41 | 1.03 | 149.14 | 0.12 | -14.28 | 1.03 | 100.00% | -11517.08% | -10579.84% | -55.68% | 986.92% | -49.44% | 0.02 | — | 6.51 | 6.38 | 1.19 | 987.00% | -5432.00% | 6344.00% | -58.34% | -3.34 | 745.62% | 0.00% | 0.00% | 0.00% | 0.12 | 0.15 | -13.36 | -4.85 |
| ZNTL | Zentalis Pharmaceuticals,… | $2.39 | 172.68M | — | -34% | — | — | -0.78 | 0.38 | 1.92 | 1.07 | — | 0.38 | 100.00% | -283.57% | -245.96% | -42.83% | -4301.81% | -33.43% | 0.13 | — | 7.32 | 7.13 | -0.05 | -4787.00% | — | -1791.00% | -132.25% | -3.24 | -3849.27% | 0.00% | 0.00% | 6.95% | 1.04 | 1.16 | -2.95 | -2.98 |
About Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- CEO
- Garo H. Armen
- Employees
- 316
- Beta
- 1.61
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.94 ÷ $3.84) − 1 = -75.52% (DCF, example).